• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Sal Patel, JD: How Sandoz v Amgen Changed the Biosimilars Landscape

Video

Sal Patel, JD, partner at Schiff Hardin, LLP, explains how the Supreme Court's 2017 ruling in Sandoz v Amgen changed the biosimilars landscape.

Transcript

How has last year’s Supreme Court ruling in Sandoz v Amgen changed the biosimilars landscape?

Well, it changes the biosimilar landscape in that now, biosimilar developers can go ahead and file declaratory judgment actions. They don’t need to participate in that long and tortuous patent dance that was required. I think it makes it a little bit easier for biosimilar developers.

Recent Videos
Travis Brewer, Texas Oncology
Josh Canavan, PharmD, head of pharmacy at RazorMetrics
Tiago Biachi, MD, PhD
Elie Bahou, MD, PhD
Steve Pickette, PharmD
Sophia Humphreys, PharmD
Sophia Humphreys, PharmD
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Ivo Abraham, PhD, RN.
Related Content
© 2025 MJH Life Sciences

All rights reserved.